Studying the effect of a new type of honey eye drop on dry eye in patients with dry eye

To determine the effect of 1 percent honey drops on the treatment of dry eye

Clinical trial with control group, with parallel groups, Triple blinded and randomized using random number table , phase 3 on 80 patients.

80 dry eye patients referred to the Poostchi ophthalmology clinic will be included in the study and randomly assigned to two groups (treatment and control). Patients are treated with honey drops or routine treatment (artificial tear drops, as a control group) for 1month and are followed-up . The blinding of study will be Triple blinded and include patients, the doctor, and the data analyst.

Inclusion criteria: Patients with dry eye syndrome (regardless of age and sex) clinically diagnosed by ophthalmologist, Tear secretion test should be less than or equal to 5 mm, Tear break time is less than or equal to 10 seconds. Exclusion criteria: Blepharitis, meibomian disorder, history of tetracycline and oral corticosteroid use in the last 3 months, ocular surface disorders, history of previous surgery and allergies

Intervention group: treatment with honey drops; including 1% honey (made from Gavan honey, produced by "Kandu Asal" company in Tearlose artificial tear drops), three times a day, one drop each time for one month. Honey drops will be prepared in the clean room of Shiraz University of Medical Sciences. Control group: standard treatment including Tearlose artificial tears, three times a day, one drop each time for one month.

Tear break-up time, Basic tear secretion rate, corneal staining

We assigned patients a code from 1 to 80. Then we used a table of random numbers to select 40 numbers. For the 40 selected patients, the Honey eye drop was used for the treatment. In the other 40 patients, the (artificial tear) was used.

First, informed consent was obtained from the patients .In order to blind, the desired drops are provided to patients in similar packages and in coded form, and patients will not be aware of the content of their medication. Patients will be aware that they will be randomly assigned to one of two treatment groups, but will be unaware of which treatment will be provided in that group. The physician also knows that patients will be anesthetized in two different ways, but will not know which procedure will be performed for each patient. The data collection officer, analyst and outcome assessor will collect and analyze information based on groups 1, 2 and will not be aware of the type of treatment provided in the groups. They will be kept blind.